Stocktoria
Inhibikase Therapeutics, Inc. IKT
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2020-12-23
Chart by TradingView
2/9
Piotroski F — financial health
—
Altman Z″ — distress risk
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | — | $0 | $260,501 | $123,440 | $3.1M |
| Operating income | -$52.0M | -$28.6M | -$20.1M | -$18.1M | -$14.8M |
| Net income | -$48.3M | -$27.5M | -$19.0M | -$18.1M | -$14.8M |
| Operating cash flow | -$27.8M | -$19.1M | -$18.1M | -$17.4M | -$14.3M |
| Free cash flow | -$27.8M | -$19.1M | -$18.1M | -$17.6M | -$14.3M |
| Total assets | $181.2M | $98.6M | $14.5M | $24.9M | $42.5M |
| Total liabilities | $8.3M | $3.7M | $3.5M | $3.9M | $4.1M |
| Shareholders' equity | $172.9M | $94.9M | $11.0M | $21.0M | $38.4M |
| Ratios | |||||
| Operating margin | — | — | -7712.0% | -14686.2% | -476.2% |
| Net margin | — | — | -7304.7% | -14625.9% | -476.9% |
| FCF margin | — | — | -6947.9% | -14253.4% | -461.1% |
| Return on assets | -26.6% | -27.9% | -131.2% | -72.4% | -34.8% |
| Return on equity | -27.9% | -29.0% | -173.3% | -85.8% | -38.5% |
| Debt / equity | — | — | 0.03× | — | 0.01× |
| Current ratio | 21.70 | 26.37 | 4.13 | 6.59 | 10.47 |
| Revenue growth | — | -100.0% | 111.0% | -96.0% | 343.9% |
Notable holders (13F)
| Investor | Shares | Value |
|---|---|---|
| Point72 Asset Management, L.P. | 40,383 | $67,843 |
| RENAISSANCE TECHNOLOGIES LLC | 16,500 | $27,720 |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: n/a
Not applicable (financials/insurer or missing inputs).
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001750149 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.